{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:51:18Z","timestamp":1780404678373,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Research Project of Education Department of Guizhou Province","award":["QianJiaoJi [2023]037"],"award-info":[{"award-number":["QianJiaoJi [2023]037"]}]},{"DOI":"10.13039\/501100005329","name":"Natural Science Foundation of Guizhou Province","doi-asserted-by":"publisher","award":["QianKeHe Basics ZK [2023] 208"],"award-info":[{"award-number":["QianKeHe Basics ZK [2023] 208"]}],"id":[{"id":"10.13039\/501100005329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005329","name":"Natural Science Foundation of Guizhou Province","doi-asserted-by":"publisher","award":["Qiankehe Cooperation Platform talents [2021] Postdoctoral Station 007"],"award-info":[{"award-number":["Qiankehe Cooperation Platform talents [2021] Postdoctoral Station 007"]}],"id":[{"id":"10.13039\/501100005329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005329","name":"Natural Science Foundation of Guizhou Province","doi-asserted-by":"publisher","award":["QianKeHe Basics ZK [2023] Key 042"],"award-info":[{"award-number":["QianKeHe Basics ZK [2023] Key 042"]}],"id":[{"id":"10.13039\/501100005329","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Innovation Talent Team Project","award":["GZYTD [2024] 003"],"award-info":[{"award-number":["GZYTD [2024] 003"]}]},{"name":"Subject Excellent Reserve Talent Project","award":["gyfyxkrc-2023-14"],"award-info":[{"award-number":["gyfyxkrc-2023-14"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02304-w","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T06:03:41Z","timestamp":1744437821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of maintenance or consolidation therapy for multiple myeloma based on proteasome inhibitors: a meta-analysis"],"prefix":"10.1007","volume":"16","author":[{"given":"Dan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshuang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanju","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"issue":"1","key":"2304_CR1","first-page":"3","volume":"9","author":"SA Padala","year":"2021","unstructured":"Padala SA, Barsouk A, Barsouk A, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci (Basel). 2021;9(1):3.","journal-title":"Med Sci (Basel)"},{"issue":"4","key":"2304_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41571-021-00593-y","volume":"19","author":"AK Dutta","year":"2022","unstructured":"Dutta AK, Alberge JB, Sklavenitis-Pistofidis R, et al. Single-cell profiling of tumour evolution in multiple myeloma\u2014opportunities for precision medicine. Nat Rev Clin Oncol. 2022;19(4):223\u201336.","journal-title":"Nat Rev Clin Oncol"},{"issue":"14","key":"2304_CR3","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1182\/bloodadvances.2022008345","volume":"7","author":"S Findlay","year":"2023","unstructured":"Findlay S, Nair R, Merrill RA, et al. The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma. Blood Adv. 2023;7(14):3485\u2013500.","journal-title":"Blood Adv"},{"issue":"22","key":"2304_CR4","doi-asserted-by":"publisher","first-page":"5741","DOI":"10.3390\/cancers13225741","volume":"13","author":"F Mannino","year":"2021","unstructured":"Mannino F, Pallio G, Corsaro R, et al. Beta-caryophyllene exhibits anti-proliferative effects through apoptosis induction and cell cycle modulation in multiple myeloma cells. Cancers (Basel). 2021;13(22):5741.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2304_CR5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/bjh.16674","volume":"191","author":"\u00d8O Langseth","year":"2020","unstructured":"Langseth \u00d8O, Myklebust T\u00c5, Johannesen TB, et al. Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982\u20132017. Br J Haematol. 2020;191(3):418\u201325.","journal-title":"Br J Haematol"},{"key":"2304_CR6","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Prim. 2017;3:17046. https:\/\/doi.org\/10.1038\/nrdp.2017.46.","journal-title":"Nat Rev Dis Prim"},{"issue":"3","key":"2304_CR7","first-page":"342","volume":"108","author":"Y Wang","year":"2015","unstructured":"Wang Y, Yang F, Shen Y, et al. Maintenance therapy with immunomodulatory drugs in multiple myeloma: a meta-analysis and systematic review. J Natl Cancer Inst. 2015;108(3):342.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2304_CR8","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/ejh.13496","volume":"105","author":"AK Balitsky","year":"2020","unstructured":"Balitsky AK, Karkar A, McCurdy A, et al. Maintenance therapy in transplant ineligible adults with newly-diagnosed multiple myeloma: a systematic review and meta-analysis. Eur J Haematol. 2020;105(5):626\u201334.","journal-title":"Eur J Haematol"},{"issue":"21","key":"2304_CR9","doi-asserted-by":"publisher","first-page":"15674","DOI":"10.3390\/ijms242115674","volume":"24","author":"HN Abramson","year":"2023","unstructured":"Abramson HN. Immunotherapy of multiple myeloma: current status as prologue to the future. Int J Mol Sci. 2023;24(21):15674.","journal-title":"Int J Mol Sci"},{"key":"2304_CR10","doi-asserted-by":"publisher","first-page":"101929","DOI":"10.1016\/j.ctrv.2019.101929","volume":"82","author":"I Ntanasis-Stathopoulos","year":"2020","unstructured":"Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, Dimopoulos MA, et al. Multiple myeloma: role of autologous transplantation. Cancer Treat Rev. 2020;82:101929.","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"2304_CR11","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1038\/s41375-023-01998-7","volume":"37","author":"JN N\u00f8rgaard","year":"2023","unstructured":"N\u00f8rgaard JN, Abildgaard N, Lys\u00e9n A, et al. Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation. Leukemia. 2023;37(10):2107\u201314.","journal-title":"Leukemia"},{"issue":"2","key":"2304_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","volume":"10","author":"MA Dimopoulos","year":"2020","unstructured":"Dimopoulos MA, Jakubowiak AJ, McCarthy PL, et al. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2020;10(2):17.","journal-title":"Blood Cancer J"},{"issue":"8","key":"2304_CR13","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1038\/s41401-021-00816-z","volume":"43","author":"DC Xu","year":"2022","unstructured":"Xu DC, Yang L, Zhang PQ, et al. Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment. Acta Pharmacol Sin. 2022;43(8):2128\u201338.","journal-title":"Acta Pharmacol Sin"},{"issue":"6","key":"2304_CR14","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3390\/cancers15061682","volume":"15","author":"P Weir","year":"2023","unstructured":"Weir P, Donaldson D, McMullin MF, et al. Metabolic alterations in multiple myeloma: from oncogenesis to proteasome inhibitor resistance. Cancers (Basel). 2023;15(6):1682.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2304_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/cancers12020265","volume":"12","author":"I Shigeki","year":"2020","unstructured":"Shigeki I. Proteasome inhibitors for the treatment of multiple myeloma. Cancers. 2020;12(2):265.","journal-title":"Cancers"},{"issue":"2","key":"2304_CR16","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1124\/pr.117.015370","volume":"71","author":"TA Thibaudeau","year":"2019","unstructured":"Thibaudeau TA, Smith DM. A practical review of proteasome pharmacology. Pharmacol Rev. 2019;71(2):170\u201397.","journal-title":"Pharmacol Rev"},{"issue":"2","key":"2304_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.respe.2021.01.007","volume":"69","author":"S Zoukal","year":"2021","unstructured":"Zoukal S, Tsoumbou-Bakana G, Traore B, et al. Neonatal healthcare associated-infections in the Maghreb. A systematic review and meta-analysis. Rev Epidemiol Sante Publique. 2021;69(2):88\u201395.","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"Pt A","key":"2304_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","volume":"45","author":"R DerSimonian","year":"2015","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015;45(Pt A):139\u201345.","journal-title":"Contemp Clin Trials"},{"issue":"6","key":"2304_CR19","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"M Cavo","year":"2020","unstructured":"Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7(6):e456\u201368.","journal-title":"Lancet Haematol"},{"issue":"1","key":"2304_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/bjh.14637","volume":"178","author":"O Sezer","year":"2017","unstructured":"Sezer O, Beksac M, Hajek R, et al. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study. Br J Haematol. 2017;178(1):61\u201371.","journal-title":"Br J Haematol"},{"issue":"23","key":"2304_CR21","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1182\/blood-2012-11-464503","volume":"121","author":"UH Mellqvist","year":"2013","unstructured":"Mellqvist UH, Gimsing P, Hjertner O, et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood. 2013;121(23):4647\u201354.","journal-title":"Blood"},{"issue":"1","key":"2304_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2012-02-408898","volume":"120","author":"M Cavo","year":"2012","unstructured":"Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120(1):9\u201319.","journal-title":"Blood"},{"issue":"9758","key":"2304_CR23","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"M Cavo","year":"2010","unstructured":"Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376(9758):2075\u201385.","journal-title":"Lancet"},{"issue":"9","key":"2304_CR24","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1080\/10428194.2019.1579322","volume":"60","author":"N Horvath","year":"2019","unstructured":"Horvath N, Spencer A, Kenealy M, et al. Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study. Leuk Lymphoma. 2019;60(9):2122\u201333.","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"2304_CR25","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial. J Clin Oncol. 2012;30(24):2946\u201355.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2304_CR26","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Bringhen S, Larocca A, et al. Bortezomib melphalan prednisone thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol. 2014;32(7):634\u201340.","journal-title":"J Clin Oncol"},{"issue":"10168","key":"2304_CR27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","volume":"393","author":"MA Dimopoulos","year":"2019","unstructured":"Dimopoulos MA, Gay F, Schjesvold F, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019;393(10168):253\u201364.","journal-title":"Lancet"},{"issue":"34","key":"2304_CR28","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1200\/JCO.20.02060","volume":"38","author":"MA Dimopoulos","year":"2020","unstructured":"Dimopoulos MA, \u0160pi\u010dka I, Quach H, et al. Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial. J Clin Oncol. 2020;38(34):4030\u201341.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2304_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","volume":"91","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91(1):101\u201319.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2304_CR30","first-page":"131","volume":"29","author":"M Shen","year":"2021","unstructured":"Shen M, Huang Z, Zhang J, et al. Clinical observation of bortezomib maintenance therapy in 25 patients with non-transplanted multiple myeloma. J Exp Hematol. 2021;29(1):131\u20136.","journal-title":"J Exp Hematol"},{"issue":"1","key":"2304_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/ejh.13506","volume":"106","author":"RD Parrondo","year":"2021","unstructured":"Parrondo RD, Reljic T, Iqbal M, et al. Efficacy of proteasome inhibitor-based maintenance following autologous transplantation in multiple myeloma: A systematic review and meta-analysis. Eur J Haematol. 2021;106(1):40\u20138.","journal-title":"Eur J Haematol"},{"issue":"3","key":"2304_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41408-020-0298-1","volume":"10","author":"S Zhang","year":"2020","unstructured":"Zhang S, Kulkarni AA, Xu B, et al. Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis. Blood Cancer J. 2020;10(3):33.","journal-title":"Blood Cancer J"},{"issue":"1","key":"2304_CR33","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1186\/s12885-023-11553-3","volume":"23","author":"X Gao","year":"2023","unstructured":"Gao X, Zeng H, Zhao X, et al. Efficacy and safety of venetoclax in patients with relapsed\/refractory multiple myeloma: a meta-analysis. BMC Cancer. 2023;23(1):1058.","journal-title":"BMC Cancer"},{"issue":"7","key":"2304_CR34","first-page":"1957","volume":"106","author":"GH Jackson","year":"2021","unstructured":"Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III. Myeloma XI trial Haematologica. 2021;106(7):1957\u201367.","journal-title":"Myeloma XI trial Haematologica"},{"issue":"6","key":"2304_CR35","first-page":"3073","volume":"7","author":"M Gao","year":"2014","unstructured":"Gao M, Gao L, Yang G, et al. Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials. Int J Clin Exp Pathol. 2014;7(6):3073\u201380.","journal-title":"Int J Clin Exp Pathol"},{"issue":"9","key":"2304_CR36","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802\u201324.","journal-title":"Am J Hematol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02304-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02304-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02304-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T21:22:13Z","timestamp":1744492933000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02304-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2304"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02304-w","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]},"assertion":[{"value":"1 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"519"}}